The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile.
Clinical benefit was observed with almonertinib (HS-10296) as treatment of patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed on previous EGFR tyrosine kinase inhibitors (TKIs), according to findings from the phase III APOLLO study presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting.
The agent also displayed an overall favorable safety profile. Read more.